IP Library Granted Patent US 11,821,039
Granted Patent B2
US 11,821,039 · App. 15/930,267 · Granted Nov 21, 2023

Detecting neoplasm

Inventors: David A. Ahlquist (Rochester, MN); John B. Kisiel (Rochester, MN); William R. Taylor (Lake City, MN); Tracy C. Yab (Rochester, MN); Douglas W. Mahoney (Elgin, MN); Graham P. Lidgard (Madison, WI); Hatim T. Allawi (Middleton, WI)
Assignees: Mayo Foundation for Medical Education and Research; Exact Sciences Corporation
C12Q1/6886C12Q2600/112C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,821,039
App. No.
15/930,267
Granted
Nov 21, 2023
Kind
B2
Abstract

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.

Claims (8)

1. A method comprising:

extracting genomic DNA from a biological sample obtained from an individual;

treating the extracted genomic DNA with bisulfite;

amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for NDRG4, primers specific for a CpG site for CD1 D, and primers specific for a CpG site for GRIN2D; and

measuring a methylation level of the CpG site for NDRG4, the CpG site for CD1 D, and the CpG site for GRIN2D.

2. The method of claim 1 , wherein the biological sample is a stool sample, an esophageal tissue sample, a tissue sample, a pancreatic juice sample, a pancreatic cyst fluid sample, a blood sample, or a urine sample.

3. The method of claim 1 , wherein measuring a methylation level of the CpG site for NDRG4, the CpG site for CD1D, and the CpG site for GRIN2D is determined by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genomic sequencing PCR.

4. The method of claim 1 , wherein the biological sample was obtained from an individual having or suspected of having or having a gastrointestinal neoplasm, a colorectal neoplasm, a pancreas neoplasm, a stomach neoplasm, and/or an esophagus neoplasm.

Assignments (6)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0249) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: EXACT SCIENCES CORPORATION
Reel/Frame 075288/0393 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: EXACT SCIENCES CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0249 →
MERGER Recorded Jan 24, 2022
From: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 058745/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2020
From: EXACT SCIENCES CORPORATION
To: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
Reel/Frame 054010/0823 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: AHLQUIST, DAVID A.; KISIEL, JOHN B.; TAYLOR, WILLIAM R.; YAB, TRACY C.; MAHONEY, DOUGLAS W.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 053999/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: LIDGARD, GRAHAM P.; ALLAWI, HATIM T.
To: EXACT SCIENCES CORPORATION
Reel/Frame 053999/0230 →